The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavir in therapy in patients with HCV 1 genotype infection
Background: Direct-acting antiviral drugs (DAA) regimen improve the SVR rate. However, adverse effects often lead to therapy interruption.






